Bio-Rad Laboratories (BIO) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bio-Rad Laboratories (BIO) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 13.3% versus a loss of 26.6%. Over five years, BIO leads with a -52.2% price change compared with -93.0% for PACB. Bio-Rad Laboratories is the larger company by market cap ($9.65 billion vs $508.9 million), about 19.0 times the size, while Pacific Biosciences of California is growing revenue faster (+3.9% vs +0.7%).
Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -341.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO | PACB |
|---|---|---|
| Share price | $358.90 | $1.63 |
| Market cap | $9.65B | $508.95M |
| 1-day change | -2.34% | -7.39% |
| YTD return | +18.45% | -12.83% |
| 1-year return | +13.32% | -26.58% |
| 5-year return | -52.16% | -93.01% |
| P/E ratio (TTM) | 9.54 | — |
| Forward P/E | 36.23 | — |
| EPS (TTM) | $37.64 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $160.00M |
| Revenue growth (YoY) | +0.65% | +3.89% |
| Net income (latest FY) | $759.90M | $-546.38M |
| Gross margin | 51.87% | 28.61% |
| Operating margin | 1.83% | -346.15% |
| Net margin | 29.42% | -341.47% |
| 52-week high | $396.23 | $3.44 |
| 52-week low | $236.73 | $1.07 |
| Distance from 52-week high | -9.42% | -52.62% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -0.62% | +68.10% |
| Average volume | 257.70K | 13.23M |
| Shares outstanding | 21.83M | 312.24M |
| Employees | 7,450 | 485 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 19.0 times larger than Pacific Biosciences of California by market value ($9.65B vs $508.95M).
- BIO has outperformed PACB by 39.9 percentage points over the past year.
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
BIO vs PACB FAQ
Which is bigger, Bio-Rad Laboratories or Pacific Biosciences of California?
Bio-Rad Laboratories (BIO) is larger, with a market capitalization of $9.65B compared with $508.95M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, BIO or PACB?
BIO returned +13.32% over the past 12 months, compared with -26.58% for PACB (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.